3Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007.CA Cancer J Clin,2007,57(1):43-66.
4Gaddueei A,Cosio S,Zola P,et al.Surveillance procedures for patients treated for epithelial ovarian cancer:a review of the literature.Int J Gyneeol Cancer,2007,17(1):21-31.
5Renehan AG,Tyson M,Egger M,et al.Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies.Lancet,2008,371(9612):569-578.
6Heintz AP,Odicino F,Maisonneuve P,et al.Carcinoma of the ovary.Int J Gynaeeol Obstet,2003,83 Suppl 1:135-166.
7Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.Cancer Res,2003,63(13):3695-3700.
8Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol,2008,108(2):402-408.
9Moore RG,McMeekin DS,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol,2009,112(1):40-46.
10Foster T,Brown TM,Chang J,et al.A review of the current evidence for naaintenanee therapy in ovarian cancer.Gynecol Oncol,2009,115(2):290-301.
